Literature DB >> 279016

Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.

D Bartfeld, S Fuchs.   

Abstract

Specific immunosuppression of experimental autoimmune myasthenia gravis (EAMG) was achieved by the use of a denatured preparation of the acetylcholine receptor (AcChoR) that did not in itself induce the disease. Torpedo californica AcChoR was irreversibly denatured by complete reduction and carboxymethylation in 6 M guanidine hydrochloride. Rabbits immunized with reduced carboxymethylated receptor (RCM-AcChoR) produced antibodies that reacted with both RCM-AcChoR and intact AcChoR. The specificity of anti-RCM-AcChoR antibodies is different from that of anti-AcChoR antibodies because the former are directed to only part of the antigenic determinants present in the intact receptor. RCM-AcChoR, which by itself is completely nonmyasthenic, was shown to be capable of both preventing the onset of EAMG and of reversing the clinical symptoms in myasthenic rabbits. In all cases the therapeutic effect of RCM-AcChoR administration on EAMG was accompanied by a change in the immunological specificity of the antibodies. The crossreactivity between AcChoR and RCM-AcChoR and the nonpathogenicity of RCM-AcChoR appear to be crucial in governing the specific immunosuppressive effects of RCM-AcChoR on EAMG.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 279016      PMCID: PMC392919          DOI: 10.1073/pnas.75.8.4006

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Immunosuppression of experimental autoimmune myasthenia gravis by azathioprine. II. Evaluation of immunological mechanism.

Authors:  R Tarrab-Hazdai; O Abramsky; S Fuchs
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

2.  The use of ACTH and corticosteroids in myasthenia gravis.

Authors:  G Genkins; P Kornfeld; K E Osserman; T Namba; D Grob; N G Brunner
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

3.  Benefit from alternate-day prednisone in myasthenia gravis.

Authors:  J R Warmolts; W K Engel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

4.  Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.

Authors:  M E Seybold; D B Drachman
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

5.  Elapid neurotoxins. Purification, characterization, and immunochemical studies of -bungarotoxin.

Authors:  D G Clark; D D Macmurchie; E Elliott; R G Wolcott; A M Landel; M A Raftery
Journal:  Biochemistry       Date:  1972-04-25       Impact factor: 3.162

6.  Immunological characterization of an irreversibly denatured acetylcholine receptor.

Authors:  D Bartfeld; S Fuchs
Journal:  FEBS Lett       Date:  1977-05-15       Impact factor: 4.124

Review 7.  Isolation and properties of acetylcholine receptors from Electrophorus and Torpedo.

Authors:  R Valderrama; C L Weill; M McNamee; A Karlin
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Immunochemical studies on acetylcholine receptor from Torpedo californica.

Authors:  A Aharonov; R Tarrab-Hazdai; I Silman; S Fuchs
Journal:  Immunochemistry       Date:  1977-02

9.  Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.

Authors:  A Aharonov; O Abramsky; R Tarrab-Hazdai; S Fuchs
Journal:  Lancet       Date:  1975-08-23       Impact factor: 79.321

10.  Effects of some immunosuppressive procedures on myasthenia gravis.

Authors:  G Matell; K Bergström; C Franksson; L Hammarström; A K Lefvert; E Möller; G von Reis; E Smith
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

View more
  13 in total

1.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide.

Authors:  N Venkatesh; S H Im; M Balass; S Fuchs; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 3.  Specificities of autoantibodies in autoimmune receptor diseases.

Authors:  M H De Baets
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.

Authors:  D Barchan; M C Souroujon; S H Im; C Antozzi; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 6.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

7.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

8.  Immune regulation of experimental myasthenia.

Authors:  S Fuchs; D Bartfeld; Z Eshhar; C Feingold; D Mochly-Rosen; D Novick; M Schwartz; R Tarrab-Hazdai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

9.  Analysis of ligand binding to the synthetic dodecapeptide 185-196 of the acetylcholine receptor alpha subunit.

Authors:  D Neumann; D Barchan; M Fridkin; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 10.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.